Sign in or create an account to add this stock to your watchlist.
About Pediapharm (CVE:PDP)
Pediapharm Inc. operates as a specialty pharmaceutical company in Canada. It distributes prescription medicines that are used to treat pathological conditions, which primarily affect children from infancy to 18 years of age; and commercializes non-prescription products, such as non-prescription drugs and medical devices that fulfill unmet medical needs of children. The company's product portfolio includes NYDA, a product for the treatment of head lice and its eggs; Relaxa to treat constipation; and naproxen suspension to treat medical pain conditions in Juvenile Arthritis. It also offers Rupatadine to treat the symptoms of allergy and urticarial; Otixal for ear infection; and Cuvposa to treat severe drooling and cerebral palsy. The company also provides marketing services related to pediatric care. Pediapharm Inc. is headquartered in Verdun, Canada.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-26.38%
Return on Assets-11.84%
Pediapharm (CVE:PDP) Frequently Asked Questions
What is Pediapharm's stock symbol?
Pediapharm trades on the Canadian Venture Exchange (CVE) under the ticker symbol "PDP."
How were Pediapharm's earnings last quarter?
Pediapharm (CVE:PDP) announced its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.01) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.01). The company earned $2.36 million during the quarter, compared to analysts' expectations of $2.60 million. Pediapharm had a negative return on equity of 26.38% and a negative net margin of 10.92%. View Pediapharm's Earnings History.
When is Pediapharm's next earnings date?
Who are some of Pediapharm's key competitors?
Some companies that are related to Pediapharm include Medicure (MPH), Oncolytics Biotech (ONC), Kitrinor Metals (SCYB), Emblem (EMMBF), Pfenex (PFNX), Oragenics (OGEN), Asterias Biotherapeutics (AST), ProMIS Neurosciences (PMN), Tissue Regenix Group (TRX), Covalon Technologies (COV), Matinas BioPharma (MTNB), Motif (MTFB), Innovation (IPIX), 4D Pharma (DDDD) and Helix Biopharma (HBP).
Who are Pediapharm's key executives?
Pediapharm's management team includes the folowing people:
- Mr. Sylvain Chretien, Pres, CEO & Director (Age 54)
- Roland Boivin, Chief Financial Officer
- Mr. Richard Labelle, VP of Sales & Marketing
- Mr. Benoît Hébert, VP of Bus. Devel. & Licensing (Age 50)
Has Pediapharm been receiving favorable news coverage?
News stories about PDP stock have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pediapharm earned a news sentiment score of 0.06 on Accern's scale. They also gave news articles about the company an impact score of 47.11 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Pediapharm?
Shares of PDP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Pediapharm's stock price today?
One share of PDP stock can currently be purchased for approximately C$0.33.
How big of a company is Pediapharm?
Pediapharm has a market capitalization of C$28.85 million.
How can I contact Pediapharm?
Pediapharm's mailing address is 1 du Commerce Pl Suite 225, VERDUN, QC H3E 1A2, Canada. The company can be reached via phone at +1-514-7622626.
MarketBeat Community Rating for Pediapharm (PDP)MarketBeat's community ratings are surveys of what our community members think about Pediapharm and other stocks. Vote "Outperform" if you believe PDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pediapharm (CVE:PDP) Analyst Ratings History
(Data available from 5/21/2016 forward)
Pediapharm (CVE:PDP) Earnings History and Estimates Chart
Pediapharm (CVE PDP) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|6/27/2018|| || || || || || || || |
|2/27/2018||Q3 2018||C($0.01)||C($0.01)||C$2.60 million||C$2.36 million||View||N/A|
|8/24/2017||Q1 2018||C($0.01)||C($0.01)||C$2.00 million||C$2.47 million||View||N/A|
|6/28/2017||Q4 2017||C($0.02)||C($0.02)||C$1.50 million||C$1.66 million||View||N/A|
|2/28/2017||Q3 2017||C($0.01)||C($0.01)||C$1.77 million||View||N/A|
|11/28/2016||Q2 2017||C($0.01)||C$1.88 million||View||N/A|
|8/18/2016||Q1 2017||C$0.02||C$0.89 million||View||N/A|
|6/27/2016||Q4 2016||C($0.02)||C$0.65 million||View||N/A|
|2/25/2016||Q3 2016||C($0.02)||C$1.02 million||View||N/A|
|11/30/2015||Q2 2016||C($0.01)||C$1.47 million||View||N/A|
|8/27/2015||Q1 2016||C($0.02)||C$0.61 million||View||N/A|
|7/20/2015||Q4 2015||C($0.03)||C$0.34 million||View||N/A|
|3/2/2015||Q3 2015||C($0.02)||C$0.92 million||View||N/A|
Pediapharm (CVE:PDP) Dividend Information
Pediapharm pays an annual dividend of C$0.14 per share, with a dividend yield of 42.42%.
Pediapharm (CVE:PDP) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Pediapharm (CVE PDP) Insider Trading and Institutional Ownership History
Pediapharm (CVE PDP) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Pediapharm (CVE PDP) News Headlines
Pediapharm (CVE:PDP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Pediapharm (CVE PDP) Stock Chart for Monday, May, 21, 2018